MSB 2.17% $1.13 mesoblast limited

MSB Trading - 2020, page-323

  1. 517 Posts.
    lightbulb Created with Sketch. 85
    I think the issue with CUV is the fact that since the approval there has been a massive lack of communication. There are issues around not approval but reimbursement being approced in certain areas in europe. This has severely limited the revenue.

    could msb share a similar fate? Not only in certain countries or Insurance funds not agreeing to reimburse the treatment but could there be issues with getting doctors on board to prescribe it? I read a post here a couple months ago suggesting someone had spoken to a group of doctors who didn't believe stem cell therapy works. While we know it does and the trials show that, could we have a hard time convincing the medical professionals to use it?
  2. This thread is closed.

    You may not reply to this discussion at this time.

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.